HYTONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYTONE (HYTONE).
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
| Metabolism | Primarily hepatic via CYP3A4; topical absorption minimal but systemic metabolism occurs if absorbed. |
| Excretion | Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal |
| Half-life | 30–60 minutes (terminal elimination half-life; short duration requires frequent dosing) |
| Protein binding | 75–85% (primarily albumin and corticosteroid-binding globulin) |
| Volume of Distribution | 0.3–0.6 L/kg (highly variable, distributes into tissues including synovial fluid) |
| Bioavailability | Oral: 10–20% (extensive first-pass metabolism); Topical: <5% (intact skin); Intramuscular: 100% |
| Onset of Action | Topical: minutes to hours; Intramuscular: 24–48 hours; Intra-articular: 12–24 hours; Oral: 2–4 hours |
| Duration of Action | Topical: 6–12 hours; Intramuscular: 6–12 days; Intra-articular: 1–2 weeks; Oral: 12–36 hours |
| Molecular Weight | 362.46 |
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for topical use. For systemic absorption (e.g., extensive application or occlusive dressings), use with caution in severe renal impairment (GFR <30 mL/min) due to potential fluid/electrolyte disturbances. |
| Liver impairment | No specific adjustment for Child-Pugh A or B. For Child-Pugh C, avoid prolonged use or large areas due to risk of systemic corticosteroid effects. |
| Pediatric use | Children >2 years: Apply thin layer to affected area 1-2 times daily for ≤2 weeks. Maximum 10% of body surface area. Infants <2 years: Use only under pediatric endocrinologist guidance due to increased systemic absorption risk. |
| Geriatric use | Use lowest effective dose for shortest duration. Avoid occlusive dressings. Monitor for skin atrophy, telangiectasia, and increased systemic effects due to thinner skin and renal/hepatic function decline. |
| 1st trimester | Topical corticosteroids (including hydrocortisone) are generally avoided in first trimester due to theoretical risk of cleft palate, but large studies show no significant increase in malformations with low-potency agents. Hytone (hydrocortisone 2.5%) is low potency; minimal systemic absorption expected from small areas, short duration. Use only if clearly needed. |
| 2nd trimester | Topical corticosteroids are generally considered safe in second trimester when used sparingly on small areas. No evidence of fetal harm. Avoid prolonged use on large areas or under occlusion. |
| 3rd trimester | Topical corticosteroids may be used in third trimester, but avoid prolonged use on large areas or under occlusion as systemic absorption could potentially affect fetal growth or cause adrenal suppression. No known teratogenic risk. |
Clinical note
Comprehensive clinical and safety monograph for HYTONE (HYTONE).
| Placental transfer | Hydrocortisone crosses the placenta; however, topical application results in negligible systemic levels. Endogenous cortisol levels are much higher. No significant risk from topical use. |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to hydrocortisone or any component of the formulationUninfected fungal, bacterial, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis)
| Precautions | Topical corticosteroids may cause reversible HPA axis suppression, Cushing's syndrome with systemic absorption, Local irritation, atrophy, striae, and telangiectasias, Use caution in pediatric patients due to greater skin surface-to-weight ratio, May mask signs of infection, Do not use on face, groin, or axillae for prolonged periods |
| Food/Dietary | None known; hydrocortisone topical is minimally absorbed systemically, so food interactions are negligible. |
Loading safety data…
| Breastfeeding |
| Topical hydrocortisone is considered compatible with breastfeeding. Apply to small areas, avoid nipple area, and do not apply to breasts if infant may ingest. Systemic absorption is minimal. Wash hands after application. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Topical corticosteroids such as hydrocortisone (HYTONE) are generally considered low risk in pregnancy. However, application to large areas, prolonged use, or occlusive dressings may increase systemic absorption. In animal studies, corticosteroids have shown teratogenicity (cleft palate). First trimester: minimal risk with topical use; avoid high potency. Second/third trimesters: use lowest potency for shortest duration. Systemic exposure sufficient to cause fetal growth restriction or adrenal suppression is unlikely with typical topical dosing. |
| Fetal Monitoring | No specific monitoring required for routine short-term topical use. If extensive or prolonged use, monitor maternal serum cortisol, blood glucose, and blood pressure. Fetal monitoring: consider ultrasound for growth restriction if high-dose systemic exposure suspected. |
| Fertility Effects | Topical corticosteroids do not impair fertility. Systemic corticosteroids may suppress gonadotropin release; no evidence for topical hydrocortisone at recommended doses. |
| Clinical Pearls |
| Hydrocortisone (HYTONE) is a low-potency topical corticosteroid. Avoid prolonged use on the face, intertriginous areas, or under occlusive dressings to prevent skin atrophy and systemic absorption. Use for short-term management of inflammatory and pruritic dermatoses. Rotate sites if long-term use is required. |
| Patient Advice | Apply a thin layer to affected skin only, avoiding healthy skin. · Do not use on broken skin or open wounds unless directed. · Wash hands after application unless treating hands. · Avoid covering treated area with bandages or wraps unless instructed. · Do not use for more than 2 weeks without re-evaluation. · Stop use and notify your doctor if irritation develops or condition worsens. · Keep out of reach of children and avoid contact with eyes. |